Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential

I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting M&A focus to revenue-generating bolt-ons and rationalizing R&D spend. The potential monetization of BIO's Sartorius stake, worth over $5 billion, appears more likely with Elliott's involvement, since the activist is also a shareholder of Sartorius. I've assigned a "Buy" rating to Bio-Rad Laboratories (BIO). Bio-Rad is making positive changes to the way it acquires companies and invests in R&D. Further improvement is likely with the recent involvement of a reputable activist. There's also a strong likelihood regarding